Analysis is based on the profiles of 56 Big Pharma and technology companies covering company background/history, financial situation, technology overview, partnering activities and pipeline overviw. 38 different technologies to create bispecific T-cell and NK cell engaging antibodies are profiled in depth. Pipeline analysis is based on the profiles of 90 drug candidates in development. Sources of information are 237 scientific references. Non-scientific sources of information, such as press releases, annual reports and presentations, are disclosed within the text with an embedded hyperlink leading to the online source of information.
Immunotherapy of cancer with T-cells oder NK cells is an area of great interest for the biopharmaceutical industry. Chimeric antigen receptor (CAR) engineered T-cell or NK cells represent one treatment modality under clinical evaluation, but the majority of Big Pharma prefers the engagement of T-cells or NK cells by recombinant monoclonal antibodies as off-the-shelf products. As only a few major pharmaceutical companies have clinically validated in-house bispecific antibody technology, partnering with technology providing companies is of great importance.
Within three years, the number of clinical stage T-cell and NK cell engagers has more than doubled and further product candidates will enter clinical evaluation in the near future.
ORDER THIS REPORT: T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis
This report will show you that there are plenty of opportunities for players in the field, including major pharmas, technology providers and investors.
This report will inform you about Big Pharma’s
38 technology companies with T-cell and NK cell engaging bispecific antibody technologies are analyzed regarding their
The profiles of 58 clinical stage and 25 non-clinical development stage T-cell and NK cell engaging bispecific antibodies form the basis of
So far, the attrition rate of T-cell and NK cell engaging antibodies is relatively low (12%). This report identified the terminated bispecific T-cell engager projects and the reasons for discontinuation.
This report also analyzes the financial „maturity“ of technology companies and their specific sources of funding. Overall, raising money for bispecific T-cell and NK cell engagers is no fundamental problem
Browse this report: https://www.marketresearchreports.com/la-merie-publishing/t-cell-nk-cell-engaging-bispecific-antibodies-2019-business-stakeholder
Browse our drug pipeline database: https://www.marketresearchreports.com/drug-pipeline
Find out how Amgen and Roche are Dominating Global Bispecific Antibodies Market
About MarketResearchReports.comMarketResearchReports.com is world’s largest store offering quality market research, SWOT analysis, competitive intelligence and industry reports. We help Fortune 500 to Start-Ups with the latest market research reports on global ®ional markets which comprise key industries, leading market players, new products and latest industry analysis & trends.
Media ContactCompany Name: MarketResearchReports.comContact Person: Sudeep ChakravartyEmail: Send EmailPhone: +1-302-703-9904Address:16192 Coastal Hwy City: LewesState: DelawareCountry: United StatesWebsite: https://www.marketresearchreports.com